Literature DB >> 9209903

Prognostic markers in resectable non-small cell lung cancer.

G M Strauss1.   

Abstract

Numerous prognostic factors have been identified in patients with resectable non-small cell lung cancer (NSCLC) which may enable stratification of patients into subsets indicating risk of recurrence following complete resection. Such prognostic markers include a variety of clinico-pathologic factors such as tumor size, modal status, and histopathologic variables. Several serum tumor markers have also proven useful. Moreover, a wide variety of molecular markers have been described over the last decade, which can be classified as molecular genetic markers, metastatic propensity markers, differentiation markers, and proliferation markers. This article reviews those prognostic markers most likely to prove clinically useful from the perspective of guiding postresection treatment strategies in early stage NSCLC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209903     DOI: 10.1016/s0889-8588(05)70441-x

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  7 in total

1.  Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer.

Authors:  Mihael Sok; Janez Ravnik; Maja Ravnik
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 2.  A decade of advances in treatment of early-stage lung cancer.

Authors:  Luca Paoletti; Nicholas J Pastis; Chadrick E Denlinger; Gerard A Silvestri
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

3.  EGFR immunoexpression, RAS immunoexpression and their effects on survival in lung adenocarcinoma cases.

Authors:  Ahmet Gokhan Gundogdu; Sevgen Onder; Pinar Firat; Riza Dogan
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

Review 4.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Authors:  C Mascaux; N Iannino; B Martin; M Paesmans; T Berghmans; M Dusart; A Haller; P Lothaire; A-P Meert; S Noel; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

5.  Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results.

Authors:  C Mascaux; B Martin; M Paesmans; T Berghmans; M Dusart; A Haller; P Lothaire; A-P Meert; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2006-06-20       Impact factor: 7.640

6.  The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Authors:  A-P Meert; M Paesmans; B Martin; P Delmotte; T Berghmans; J-M Verdebout; J-J Lafitte; C Mascaux; J-P Sculier
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

Review 7.  Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis.

Authors:  B Martin; M Paesmans; T Berghmans; F Branle; L Ghisdal; C Mascaux; A-P Meert; E Steels; F Vallot; J-M Verdebout; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.